PWPS
BCRX icon

Pinnacle Wealth Planning Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
13,040
+262
+2% +$2.37K 0.01% 736
2026
Q1 		$122K Hold
12,778
– – 0.01% 698
2025
Q4 		$99.7K Hold
12,778
– – 0.01% 790
2025
Q3 		$97K Sell
12,778
-4,184
-25% -$34.8K 0.01% 469
2025
Q2 		$152K Buy
16,962
+4,048
+31% +$37.7K 0.02% 433
2025
Q1 		$96.9K Buy
12,914
+204
+2% +$1.65K 0.01% 384
2024
Q4 		$95.6K Sell
12,710
-12,034
-49% -$91.4K 0.01% 373
2024
Q3 		$188K Buy
24,744
+1,708
+7% +$13K 0.03% 468
2024
Q2 		$142K Buy
+23,036
New +$127K 0.02% 449
2024
Q1 		– Sell
-20,561
Closed -$123K – 512
2023
Q4 		$123K Buy
+20,561
New +$119K 0.02% 440
2021
Q1 		– Sell
-143
Closed -$1K – 518
2020
Q4 		$1K Buy
+143
New +$737 ﹤0.01% 2062

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pinnacle Wealth Planning Services's BCRX Position: Q2 2026 in Review

Pinnacle Wealth Planning Services increased its BioCryst Pharmaceuticals (BCRX) stake by 2.1% in Q2 2026, buying an estimated $2.37K and bringing the position to 13,040 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #736.

Pinnacle Wealth Planning Services first reported a position in BCRX in Q4 2020 and has held it in 11 quarters since. The position peaked at $188K in Q3 2024. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Pinnacle Wealth Planning Services held 13,040 shares of BioCryst Pharmaceuticals worth $130K as of Q2 2026.
  • Pinnacle Wealth Planning Services bought 262 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.37K.
  • BioCryst Pharmaceuticals made up 0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #736 holding.
  • Pinnacle Wealth Planning Services first reported a position in BioCryst Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
  • Pinnacle Wealth Planning Services's BioCryst Pharmaceuticals position peaked at $188K in Q3 2024.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.